Latest News and Press Releases

NEW YORK and SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW) (“Perta”), a publicly traded special purpose acquisition company, announced today...

-The Definitive Proxy Statement Has Been Filed with The Securities and Exchange Commission- -Stockholders Special Meeting Scheduled for January 6, 2022- NEW YORK and SAN DIEGO, Dec. 16, 2021 ...

- Dr. Bellanti is Director of the International Center for Interdisciplinary Studies of Immunology and Professor of Pediatrics and Microbiology and Immunology at Georgetown University SAN DIEGO, Dec....

SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for...

- Dr. Catherine Blish is Professor of Medicine and Immunology and Associate Dean for Basic and Translational Research at the Stanford University School of Medicine – - Dr. Paul Spearman is...

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for...

-REVID may have use by individuals in at-home settings for rapid monitoring of respiratory viral infections- -Offering broad detection of various viral infections, such as SARS-CoV-2, RSV, and...

-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza, SARS-CoV-2, rhinovirus, RSV and pneumonia- -Intranasal immunomodulator,...

-Phase 1b study will investigate the efficacy of REVTx-99 on nasal symptoms elicited by nasal allergen challenge- -Top-line data anticipated in the first quarter of 2022- SAN DIEGO, Oct. 04, 2021 ...

- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 ...